Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - gefitinib - filmdragerad tablett - 250 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; gefitinib 250 mg aktiv substans

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

orion corporation - gefitinib - filmdragerad tablett - 250 mg - gefitinib 250 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - gefitinib - filmdragerad tablett - 250 mg - laktosmonohydrat hjälpämne; gefitinib 250 mg aktiv substans; natriumlaurilsulfat hjälpämne

Uni Eropa - Swedia - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - carcinom, non-small cell lung - antineoplastiska medel - iressa är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer med aktiverande mutationer av epidermal growth factor-receptor tyrosinkinas.

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - sorafenibtosilat - filmdragerad tablett - 200 mg - sorafenibtosilat 274 mg aktiv substans; natriumlaurilsulfat hjälpämne

Uni Eropa - Swedia - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiska medel - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad icke-småcellig lungcancer efter tidigare kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

orion corporation - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,3 mg aktiv substans; laktos (vattenfri) hjälpämne

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

orion corporation - erlotinibhydroklorid - filmdragerad tablett - 25 mg - erlotinibhydroklorid 27,3 mg aktiv substans; laktos (vattenfri) hjälpämne

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

orion corporation - erlotinibhydroklorid - filmdragerad tablett - 150 mg - laktos (vattenfri) hjälpämne; erlotinibhydroklorid 163,9 mg aktiv substans

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

qilu pharma spain s.l. - gefitinib - filmdragerad tablett - 250 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; gefitinib 250 mg aktiv substans